drugset
drugset / Trial / NCT07423975

Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke

NCT07423975 ↗

Phase 2 Not yet recruiting 159 enrolled Beijing Tiantan Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved successful recanalization after endovascular thrombectomy.

Timeline

Start
2026-03-01
Primary completion
2026-09-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 2 mg/kg Subcutaneous
Subject Anakinra Protein / enzyme biologic 100 mg Subcutaneous

Indications

ischemic stroke